Royal Bank Of Canada Avalo Therapeutics, Inc. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.0 - $10.45 $12 - $41	-4 Reduced 0.1%	3,958 $2,000
Q1 2022 May 16, 2022	SELL	$7.57 - $21.72 $78,137 - $224,193	-10,322 Reduced 72.26%	3,962 $3,000
Q4 2021 Feb 14, 2022	BUY	$19.68 - $28.68 $152,460 - $222,183	7,747 Added 118.51%	14,284 $24,000
Q3 2021 Nov 15, 2021	BUY	$26.16 - $40.68 $171,007 - $265,925	6,537 New	6,537 $15,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $103M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.